Allogeneic Astrocytoma in Immune Competent Dogs

Neoplasia

Volumn 1, Issue 2, 1999, Pages 107-112

  Berens, Michael E ^a   Giese, Alf ^b   Shapiro, Joan R ^a   Coons, Stephen W ^a  

^a ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Animal model; Astrocytoma; Glioma; Immune tolerance

Indexed keywords

ANIMAL; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; DOG; GLIA; IMMUNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; DOGS; MAGNETIC RESONANCE IMAGING; NEOPLASM TRANSPLANTATION; NEUROGLIA; TUMOR CELLS, CULTURED;

EID: 0033139510     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900020     Document Type: Article

References (60)

1. Berens ME, Rutka JT, and Rosenblum ML (1990). Brain tumor epidemiology, growth and invasion. Neurosurg Clin N Am 1, 1-18.
2. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM, and Davis FG (1999). The descriptive epidemiology of brain and central nervous system tumors in the United States. Results from CBTRUS 1990-1994. Neuro-Oncology 1, 14-25.
3. Levin VA, Gutin PH, and Leibel S (1993). Neoplasms of the Central Nervous System. In Cancer: Principles & Practice of Oncology (4th ed). VT DeVita, Jr., S Hellman and SA Rosenberg (Eds). J.B. Lippincott, Philadelphia, PA. pp. 1679-1746.
4. Davis FG, Freels S, Grutsch J, Barlas S, and Brem S (1998). Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88, 1-10.
5. Winger MJ, Macdonald DR, Schold SC, and Cairncross JG (1989). Selection bias in clinical trials of anaplastic glioma. Ann Neurol 26, 531-534.
6. Kirby S, Brothers M, Irish W, Florell R, Macdonald D, Schold C, and Cairncross G (1995). Evaluating glioma therapies: Modeling treatments and predicting outcomes. J Natl Cancer Inst 87, 1884-1888.
7. Wisoff JH, Boyett JM, Berger MS, Brant C, Li H, Yates AJ, McGuire-Cullen P, Turski PA, Sutton LN, Allen JC, Packer RJ, and Finlay JL (1998). Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: A report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 89, 52-59.
8. Vecht CJ, Avezaat CJ, van Putten WL, Eijkenboom WM, and Stefanko SZ (1990). The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 53, 466-471.
9. Alexander E, and Loeffler JS (1998). Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14, 43-52.
10. Knapp DW, and Waters DJ (1997). Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today 3, 8-11.
11. Palmer AC (1976). Comparative aspects of tumors of the central nervous system in the dog. Proc Royal Soc Med 69, 49-51.
12. Bigner DD, and Swenberg JA (1977). Experimental Tumors of the Central Nervous System. First English edition translated from W. Janisch and D. Schreiber. The Upjohn Company, Kalamazoo, MI.
13. Rubinstein LJ (1977). Correlation of animal brain tumor models with human neurooncology. NCI Monograph 46, 43-49.
14. Frenier SL, Moore MP, Kraft SL, and Gavin PR (1990). Canine intracranial astrocytomas and comparison with the human counterpart. The Small Animal Compendium 12, 1422-1433.
15. Heidner GL, Komegay JN, Page RL, Dodge RK, and Thrail DE (1991). Analysis of survival in a retrospective study of 86 dogs with brain tumors. J Vet Intern Med 5, 219-226.
16. Zaki FA (1977). Spontaneous central nervous system tumors in the dog. Vet Clin North Am 7, 153-163.
17. Turrel JM, Fike JR, LeCouteur RA, and Higgins RJ (1986). Computed tomographic characteristics of primary brain tumors in 50 dogs. J Am Vet Med Assoc 188, 851-856.
18. Kraft SL, Gavin PR, DeHaan C, Moore M, Wendung LR, and Leathers CW (1997). Retrospective review of 50 canine intracranial tumors evaluated by magnetic resonance imaging. J Vet Intern Med 11, 218-225.
19. Gavin PR, Kraft SL, DeHaan CE, Swartz CD, and Griebenow ML (1994). Large animal normal tissue tolerance with boron neutron capture. Int J Radiat Oncol Biol Phys 28, 1099-1106.
20. Gavin PR, Kraft SL, Huiskamp R, and Coderre JA (1997). A review: CNS effects and normal tissue tolerance in dogs. J Neurooncol 33, 71-80.
21. Whelan HT, Schmidt MH, Segura AD, McAuliffe TL, Bajic DM, Murray KJ, Moulder JE, Strother DR, Thomas JP, and Meyer GA (1993). The role of photodynamic therapy in posterior fossa brain tumors. A preclinical study in a canine glioma model. J Neurosurg 79, 562-568.
22. Berens ME, Bjotvedt G, Levesque DC, Rief MD, Shapiro JR, and Coons SW (1993). Tumorigenic, invasive, karyotypic and immunological characterization of clonal cell lines derived from a spontaneous canine anaplastic astrocytoma. In Vitro Cell Dev Biol Anim 29A, 310-318.
23. Devilee P, Van Leeuwen IS, Voesten A, Rutteman GR, Vos JH, and Cornelisse CJ (1994). The canine p53 gene is subject to somatic mutations in thyroid carcinoma. Anticancer Res 14, 2039-2046.
24. Van Leeuwen IS, Hellmen E, Cornelisse CJ, Van den Burgh B, and Rutteman GR (1996). P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog. Anticancer Res 16, 3737-3744.
25. Veldhoen N, and Milner J (1998). Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. Oncogene 16, 1077-1084.
26. Billingham RE, Brent L, and Medawar PB (1953). Actively acquired tolerance of foreign cells. Nature 172, 603-606.
27. Ramsdell F, and Fowlkes BJ (1992). Maintenance of in vivo tolerance by persistence of antigen. Science 257, 1130-1134.
28. Fadem BH, Hill HZ, Huselton CA, and Hill GJ (1988). Transplantation, growth, and regression of mouse melanoma xenografts in neonatal marsupials. Cancer Invest 6, 403-408.
29. Edwards RG, Jauniaux E, Binns RM, Layton M, Jurkovic D, Grillo TA, and Campbell S (1995). Induced tolerance and chimaerism in human fetuses using coelocentesis: A medical opportunity to avert genetic disease? Hum Reprod Update 1, 419-427.
30. Alferink J, Tafuri A, Vestweber D, Hallmann R, Hammerling GJ, and Arnold B (1998). Control of neonatal tolerance to tissue antigens by peripheral T cell trafficking. Science 282, 1338-1341.
31. Kim HB, Shaaban AF, Yang EY, Liechty KW, and Flake AW (1998). Microchimerism and tolerance after in utero bone marrow transplantation in mice. J Surg Res 77, 1-5.
32. Tizard I (1992). Veterinary Immunology: An Introduction (4th ed). WB Saunders Co., Philadelphia, PA.
33. Yeager AE, Mohammed HO, Meyers-Wallen V, Vannerson L, and Concannon PW (1992). Ultrasonographic appearance of the uterus, placenta, fetus, and fetal membranes throughout accurately timed pregnancy in Beagles. Am J Vet Res 53, 342-351.
34. Lim RK, Liu C, and Moffitt RL (1960). A Stereotaxic Atlas of the Dog's Brain. Charles C. Thomas, Springfield, MO.
35. Sobol RE, Fakhrai H, Shawler D, Gjerset R, Dorigo O, Carson C, Khaleghi T, Koziol J, Shiftan TA, and Royston I (1995). Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2, 164-167.
36. Ojeda VJ, and Moutaery KR (1998). Neuropathological biopsy diagnoses in clinical practice: How thorough and reproducible are they? Pathology 30, 328-329.
37. Schiffer D (1998). Classification and biology of astrocytic gliomas. Forum (Genova) 8, 244-255.
38. Herpers MJ, Budka H, and McCormick D (1984) Production of glial fibrillary acidic protein (GFAP) by neoplastic cells: adaptation to the microenvironment. Acta Neuropathol (Berl) 64, 333-338.
39. Gomes D, de Nechaud B, Maunoury R, Moura Neto V, Brigaudeau C, Labrousse F, and Dupouey P (1997). Glial fibrillary acidic protein expression in a new human glioma cell line in culture before and after xenogenic transplantation into nude mice. Acta Neuropathol (Berl) 94, 376-384.
40. Pekny M, Eliasson C, Chien CL, Kindblom LG, Liem R, Hamberger A, and Betsholtz C (1998). GFAP-deficient astrocytes are capable of stellation in vitro when cocultured with neurons and exhibit a reduced amount of intermediate filaments and an increased cell saturation density. Exp Cell Res 239, 332-343.
41. Scherer HJ (1940). The forms of growth in gliomas and their practical significance. Brain 63, 1-35.
42. Laerum OD, Bjerkvig R, Steinsvag SK, and de Ridder L (1984). Invasiveness of primary brain tumors. Cancer Metastasis Rev 3, 223-236.
43. Laws ER, Jr., Goldberg WJ, and Bernstein JJ (1993). Migration of human malignant astrocytoma cells in the mammalian brain: Scherer revisited. Int J Devel Neurosci 11, 691-697.
44. Thomson AW, Lu L, Murase N, Demetris AJ, Rao AS, and Starzl TE (1995). Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (Dayt) 13, 622-639.
45. Ruiz P, Nassiri M, Viciana AL, Padmanabhan J, and Streilein JW (1995). Characterization of donor chimerism, alloreactive host T cells and memory cell development in thymi from mice resistant to neonatal transplantation tolerance. J Immunol 154, 633-643.
46. Ruiz P, Nassiri M, Gregorian S, Viciana AL, and Streilein JW (1996). Neonatal transplantation tolerance is associated with a systemic reduction in memory cells, altered chimeric cell phenotype, and modified eicosanoid and cytokine production. Transplantation 61, 1198-1205.
47. Crafts D, and Wilson CB (1977). Animal models for brain tumors. Natl Cancer Inst Monograph 46, 11-17.
48. Peterson DL, Sheridan PJ, and Brown WE (1994). Animal models for brain tumors: historical perspectives and future directions. J Neurosurg 80, 865-876.
49. Krushelnycky BW, Farr-Jones MA, Mielke B, McKean JD, Weir BK, and Petruk KC (1991). Development of a large-animal human brain tumor xenograft model in immunosuppressed cats. Cancer Res 51, 2430-2437.
50. Andreansky S, He B, van Cott J, McGhee J, Markert JM, Gillespie GY, Roizman B, and Whitley RJ (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther 5, 121-130.
51. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, Dranoff G, Breakefield XO, and Yu JS (1997). Vaccination for experimental gliomas using GM-CSF-transduced glioma cells. Cancer Gene Ther 4, 345-352.
52. Tseng SH, Hwang LH, and Lin SM (1997). Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines. J Immunother 20, 334-342.
53. Salcman M, Scott EW, Schepp RS, Knipp HC, and Broadwell RD (1982). Transplantable canine glioma model for use in experimental neuro-oncology. Neurosurgery 11, 372-381.
54. Guidance for Industry (1997). S6 Preclinical Safety Evaluation Of Biotechnology-Derived Pharmaceuticals. Drug Information Branch (HFD-210), Center for Drug Evaluation and Research (CDER), Rockville, MD. pp. 1-14.
55. Williams JA, Dillehay LE, Tabassi K, Sipos E, Fahlman C, and Brem H (1997). Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol 32, 181-192.
56. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, and Oldfield EH (1994). Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 91, 2076-2080.
57. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, and Neuwelt EA (1996). Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery 38, 746-752.
58. Groothuis DR, Ward S, Itskovich AC, Dobrescu C, Allen CV, Dills C, and Levy RM (1999). Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 90, 321-331.
59. Fung LK, Ewend MG, Sills A, Sipos EP, Thompson R, Watts M, Colvin OM, Brem H, and Saltzman WM (1998). Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58, 672-684.
60. Garcia-Contreras L, Abu-Izza K, and Lu DR (1997). Biodegradable cisplatin microspheres for direct brain injection: preparation and characterization. Pharm Dev Technol 2, 53-65.